These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 32738411)

  • 1. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
    Tang K; Jia YN; Yu B; Liu HM
    Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
    Wang M; Lu J; Wang M; Yang CY; Wang S
    J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
    Yuan X; Bu H; Zhou J; Yang CY; Zhang H
    J Med Chem; 2020 Oct; 63(20):11368-11396. PubMed ID: 32460492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
    Song Y; Zhao M; Zhang H; Yu B
    Pharmacol Ther; 2022 Feb; 230():107966. PubMed ID: 34403682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
    Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
    Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
    Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
    Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery.
    Song Y; Yang X; Wang S; Zhao M; Yu B
    Med Res Rev; 2022 Sep; 42(5):1781-1821. PubMed ID: 35575058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel PROTACs for degradation of SHP2 protein.
    Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
    Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting SHP2 phosphatase in hematological malignancies.
    Kanumuri R; Kumar Pasupuleti S; Burns SS; Ramdas B; Kapur R
    Expert Opin Ther Targets; 2022 Apr; 26(4):319-332. PubMed ID: 35503226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
    Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
    Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
    Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
    ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.
    Song Y; Wang S; Zhao M; Yang X; Yu B
    J Med Chem; 2022 Feb; 65(4):3066-3079. PubMed ID: 35157464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
    LaMarche MJ; Acker M; Argintaru A; Bauer D; Boisclair J; Chan H; Chen CH; Chen YN; Chen Z; Deng Z; Dore M; Dunstan D; Fan J; Fekkes P; Firestone B; Fodor M; Garcia-Fortanet J; Fortin PD; Fridrich C; Giraldes J; Glick M; Grunenfelder D; Hao HX; Hentemann M; Ho S; Jouk A; Kang ZB; Karki R; Kato M; Keen N; Koenig R; LaBonte LR; Larrow J; Liu G; Liu S; Majumdar D; Mathieu S; Meyer MJ; Mohseni M; Ntaganda R; Palermo M; Perez L; Pu M; Ramsey T; Reilly J; Sarver P; Sellers WR; Sendzik M; Shultz MD; Slisz J; Slocum K; Smith T; Spence S; Stams T; Straub C; Tamez V; Toure BB; Towler C; Wang P; Wang H; Williams SL; Yang F; Yu B; Zhang JH; Zhu S
    J Med Chem; 2020 Nov; 63(22):13578-13594. PubMed ID: 32910655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
    Kerr DL; Haderk F; Bivona TG
    Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A patent review of SHP2 allosteric inhibitors (2018-present).
    Petrocchi A; Ciammaichella A
    Expert Opin Ther Pat; 2024 May; 34(5):383-396. PubMed ID: 38842843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
    Song Z; Wang M; Ge Y; Chen XP; Xu Z; Sun Y; Xiong XF
    Acta Pharm Sin B; 2021 Jan; 11(1):13-29. PubMed ID: 33532178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
    Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
    J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Degradation of the Oncogenic Phosphatase SHP2.
    Vemulapalli V; Donovan KA; Seegar TCM; Rogers JM; Bae M; Lumpkin RJ; Cao R; Henke MT; Ray SS; Fischer ES; Cuny GD; Blacklow SC
    Biochemistry; 2021 Aug; 60(34):2593-2609. PubMed ID: 34411482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
    Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
    Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
    Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
    J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.